Assessing the Correlation between Survivin and Bcl-2 Expression to Pathological Malignancy and Anti-apoptotic Property in Glial Cell Tumors | Chapter 12 | New Horizons in Medicine and Medical Research Vol. 6
Apoptosis is controlled by a variety of variables whose mechanisms are unknown. Bcl-2 is a well-known apoptosis mediator. Survivin is also a new noble family inhibitor of apoptosis protein (IAP) that controls apoptosis in a different way than the Bcl-2 family. Survivin and Bcl-2 are found in a variety of human malignancies. The goal of the study was to look at the expression of survivin and Bcl-2 in glial cell tumours and see if there was a link between pathological malignancy and anti-apoptotic characteristics. This study looked at 58 patients who had glial cell tumours that had been surgically removed. The World Health Organization classification was used to classify the pathogenic kinds of glial cell tumours (WHO). Survivin was found in 60.3 percent of glioma samples, whereas Bcl-2 was found in 43.1 percent. Survivin and Bcl-2 were found to be co-expressed in 25.9% of tumour samples. Survivin expression was linked with pathological grade in astrocytic tumours (P 0.05), but not with Bcl-2 (P > 0.05). Anti-apoptosis was found in 91.4 percent, 92.0 percent, and 100 percent of patients with survivin, Bcl-2, or co-expression, respectively. These findings imply that survivin expression is linked to glioma pathological grades. Furthermore, in gliomas, survivin or Bcl-2 expression has a potent anti-apoptotic effect. Our findings suggest that survivin or Bcl-2 could be possible targets for glioma apoptosis.
Author(S) Details
Sae Min Kwon
Department of Neurosurgery, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea.
In-Suk Bae
Department of Neurosurgery, Nowon Eulji Medical Center, Eulji University, Seoul, Korea.
Choong Hyun Kim
Department of Neurosurgery, Hanyang University Guri Hospital, Guri, Gyeonggi-do, Korea.
View Book:- https://stm.bookpi.org/NHMMR-V6/article/view/6443
Comments
Post a Comment